$KPTI
Karyopharm Therapeutics Inc.

2017 Q3 Form 10-Q Financial Statement

#000119312517251322 Filed on August 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q2
Revenue $0.00 $3.000K $59.00K
YoY Change -100.0% -94.92% -60.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.820M $6.640M $5.960M
YoY Change -1.36% 11.41% -3.25%
% of Gross Profit
Research & Development $25.24M $23.12M $24.58M
YoY Change 26.86% -5.94% -8.99%
% of Gross Profit
Depreciation & Amortization $180.0K $180.0K $180.0K
YoY Change 0.0% 0.0% 20.0%
% of Gross Profit
Operating Expenses $31.06M $29.76M $30.54M
YoY Change 20.41% -2.55% -7.92%
Operating Profit -$31.06M -$29.75M -$30.48M
YoY Change 20.64% -2.38% -7.68%
Interest Expense $450.0K $410.0K $330.0K
YoY Change 45.16% 24.24% 22.22%
% of Operating Profit
Other Income/Expense, Net $428.0K $383.0K $318.0K
YoY Change 35.02% 20.44% 0.0%
Pretax Income -$30.63M -$29.37M -$30.16M
YoY Change 20.46% -2.62% -7.77%
Income Tax $13.00K $18.00K $0.00
% Of Pretax Income
Net Earnings -$30.64M -$29.39M -$30.16M
YoY Change 20.51% -2.56% -7.76%
Net Earnings / Revenue -979566.67% -51115.25%
Basic Earnings Per Share
Diluted Earnings Per Share -$650.0K -$641.3K -$838.7K
COMMON SHARES
Basic Shares Outstanding 47.14M shares 47.12M shares 35.96M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $119.4M $143.5M $122.7M
YoY Change -5.84% 16.95% -44.53%
Cash & Equivalents $54.45M $55.38M $37.72M
Short-Term Investments $65.00M $88.10M $85.00M
Other Short-Term Assets $2.300M $2.300M $1.500M
YoY Change -32.35% 53.33% -63.41%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $121.7M $145.7M $124.2M
YoY Change -6.58% 17.33% -44.86%
LONG-TERM ASSETS
Property, Plant & Equipment $2.304M $2.473M $3.170M
YoY Change -22.97% -21.99% -1.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $39.50M $37.30M $42.90M
YoY Change -20.36% -13.05% 24.71%
Other Assets $300.0K $300.0K $111.0K
YoY Change 0.33% 170.27% -72.25%
Total Long-Term Assets $42.09M $40.03M $46.70M
YoY Change -21.14% -14.29% 22.75%
TOTAL ASSETS
Total Short-Term Assets $121.7M $145.7M $124.2M
Total Long-Term Assets $42.09M $40.03M $46.70M
Total Assets $163.8M $185.8M $170.9M
YoY Change -10.81% 8.69% -35.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.890M $3.247M $4.063M
YoY Change -13.82% -20.08% -9.08%
Accrued Expenses $17.72M $12.88M $11.11M
YoY Change 43.92% 15.87% 19.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.16M $17.52M $15.52M
YoY Change 41.49% 12.86% 10.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.400M $1.500M $1.800M
YoY Change -17.65% -16.67% -5.26%
Total Long-Term Liabilities $1.400M $1.500M $1.800M
YoY Change -17.65% -16.67% -5.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.16M $17.52M $15.52M
Total Long-Term Liabilities $1.400M $1.500M $1.800M
Total Liabilities $22.60M $19.04M $17.33M
YoY Change 35.38% 9.84% 8.55%
SHAREHOLDERS EQUITY
Retained Earnings -$456.3M -$425.7M -$313.7M
YoY Change 34.53% 35.67% 59.17%
Common Stock $597.6M $592.5M $467.2M
YoY Change 18.07% 26.84% 5.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $141.2M $166.7M $153.6M
YoY Change
Total Liabilities & Shareholders Equity $163.8M $185.8M $170.9M
YoY Change -10.81% 8.69% -35.09%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$30.64M -$29.39M -$30.16M
YoY Change 20.51% -2.56% -7.76%
Depreciation, Depletion And Amortization $180.0K $180.0K $180.0K
YoY Change 0.0% 0.0% 20.0%
Cash From Operating Activities -$21.75M -$21.72M -$20.89M
YoY Change 6.98% 3.97% -25.63%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K
YoY Change -98.31%
Acquisitions
YoY Change
Other Investing Activities $20.61M -$1.140M $16.22M
YoY Change -514.69% -107.03% 1018.62%
Cash From Investing Activities $20.60M -$1.140M $16.22M
YoY Change -513.65% -107.03% 1786.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 160.0K 52.57M 240.0K
YoY Change -99.49% 21804.17% 1100.0%
NET CHANGE
Cash From Operating Activities -21.75M -21.72M -20.89M
Cash From Investing Activities 20.60M -1.140M 16.22M
Cash From Financing Activities 160.0K 52.57M 240.0K
Net Change In Cash -990.0K 29.71M -4.430M
YoY Change -116.05% -770.65% -83.72%
FREE CASH FLOW
Cash From Operating Activities -$21.75M -$21.72M -$20.89M
Capital Expenditures -$10.00K -$10.00K
Free Cash Flow -$21.74M -$20.88M
YoY Change 6.94% -24.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
3681 sqft
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
374000
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
427000
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47138861 shares
CY2014Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29933 sqft
CY2014Q1 us-gaap Security Deposit
SecurityDeposit
400000
CY2014Q1 kpti Estimated Future Security Deposit
EstimatedFutureSecurityDeposit
200000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37717000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12876000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
145724000
CY2017Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
157943000
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
779000
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2208000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
592534000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3247000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-165000
CY2017Q2 us-gaap Assets
Assets
185750000
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
103498000
CY2017Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
145000
CY2017Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
125342000
CY2017Q2 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
63 Securities
CY2017Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
125472000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55381000
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47123208 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47123208 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1025000
CY2017Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1516000
CY2017Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
292000
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2138000
CY2017Q2 us-gaap Liabilities
Liabilities
19036000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
185750000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17520000
CY2017Q2 us-gaap Long Term Investments
LongTermInvestments
37269000
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
271000
CY2017Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
80000
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2070000
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2473000
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4681000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
284000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-425660000
CY2017Q2 us-gaap Short Term Investments
ShortTermInvestments
88073000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
166714000
CY2017Q2 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
9688000
CY2017Q2 kpti Additional Area Included In Operating Sublease After Amendment
AdditionalAreaIncludedInOperatingSubleaseAfterAmendment
16234 sqft
CY2017Q2 kpti Operating Lease Property Leased Area Covered Under Amended Agreement
OperatingLeasePropertyLeasedAreaCoveredUnderAmendedAgreement
27701 sqft
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58358000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11362000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
131636000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
163239000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
480000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1845000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
528617000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4751000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-274000
CY2016Q4 us-gaap Assets
Assets
180385000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
95949000
CY2016Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
194000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
125323000
CY2016Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
58 Securities
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
125478000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49663000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41887829 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41887829 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1666000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
280000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3476000
CY2016Q4 us-gaap Liabilities
Liabilities
18142000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180385000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16476000
CY2016Q4 us-gaap Long Term Investments
LongTermInvestments
45434000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
551000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
83000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2084000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2836000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4681000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
479000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-366104000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
79889000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
162243000
CY2016Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6855000
dei Amendment Flag
AmendmentFlag
false
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-592000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5718000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
598000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
25000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59195000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation And Amortization
DepreciationAndAmortization
363000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.35
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
106000
dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12899000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59263000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1025000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
139000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1507000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1484000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-19000
us-gaap Investment Income Interest
InvestmentIncomeInterest
812000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-585000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-46429000
us-gaap Operating Expenses
OperatingExpenses
60102000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
52626000
us-gaap Net Income Loss
NetIncomeLoss
-59304000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60031000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
768000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
84000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56797000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
358000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.59
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
14000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11510000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57217000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
89000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
61564000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
303000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
60979000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47203000
us-gaap Revenue From Grants
RevenueFromGrants
71000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
75000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
233000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
70000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-503000
us-gaap Investment Income Interest
InvestmentIncomeInterest
615000
us-gaap Share Based Compensation
ShareBasedCompensation
11038000
dei Trading Symbol
TradingSymbol
KPTI
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43873892 shares
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
52323000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-595000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-20641000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
22968000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-44059000
us-gaap Operating Expenses
OperatingExpenses
57884000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
436000
us-gaap Net Income Loss
NetIncomeLoss
-57217000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57825000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
608000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
13000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
579000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
407000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
87033000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
436000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
110046000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46374000
us-gaap Revenue From Grants
RevenueFromGrants
59000
us-gaap Share Based Compensation
ShareBasedCompensation
11563000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35917486 shares
kpti Deferred Financing Costs Included In Accounts Payable
DeferredFinancingCostsIncludedInAccountsPayable
22000
CY2014Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2014Q1 kpti Number Of Additional Lease Terms Option To Renew
NumberOfAdditionalLeaseTermsOptionToRenew
1 Lease
CY2014Q1 kpti Lessee Leasing Arrangements Operating Leases Additional Extension Term
LesseeLeasingArrangementsOperatingLeasesAdditionalExtensionTerm
P5Y
CY2015Q1 kpti Operating Leases Allowance For Improvements
OperatingLeasesAllowanceForImprovements
1616000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30114000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5956000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30158000
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
329000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
30535000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-30158000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30476000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
318000
CY2016Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20000
CY2016Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
290000
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
64000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24579000
CY2016Q2 us-gaap Revenue From Grants
RevenueFromGrants
59000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35956470 shares
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29348000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6635000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29369000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
412000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
29755000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-29387000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29752000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
383000
CY2017Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
73000
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
297000
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-34000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23120000
CY2017Q2 us-gaap Revenue From Grants
RevenueFromGrants
3000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45831239 shares

Files In Submission

Name View Source Status
0001193125-17-251322-index-headers.html Edgar Link pending
0001193125-17-251322-index.html Edgar Link pending
0001193125-17-251322.txt Edgar Link pending
0001193125-17-251322-xbrl.zip Edgar Link pending
d408983d10q.htm Edgar Link pending
d408983dex311.htm Edgar Link pending
d408983dex312.htm Edgar Link pending
d408983dex321.htm Edgar Link pending
d408983dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-20170630.xml Edgar Link completed
kpti-20170630.xsd Edgar Link pending
kpti-20170630_cal.xml Edgar Link unprocessable
kpti-20170630_def.xml Edgar Link unprocessable
kpti-20170630_lab.xml Edgar Link unprocessable
kpti-20170630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending